PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

2021-03-23T18:51:39-04:00January 7th, 2020|News, Press|

IVI Comment Letter on ICER’s Proposed Methods for Curative Therapies

IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings by decision makers, specifically when short-term budget estimates may discourage investment in therapies with high long-term value, including careful consideration [...]

2019-09-16T12:50:24-04:00September 16th, 2019|News|

Watch Mark Linthicum’s “101 Course” on IVI’s New Non-Small Cell Lung Cancer Value Model

IVI's Director of Scientific Communications, Mark Linthicum, sits down with the Journal of Clinical Pathways for a webinar discussion about IVI's open-source model for assessing value in non-small cell lung cancer therapies. If you want to learn more about IVI's open-source approach to value assessment, this webinar is a great place to start. Click here to [...]

2019-03-11T17:01:06-04:00March 11th, 2019|News|

PRESS RELEASE: IVI’s Patient Research Reveals Importance of Quality of Life in Assessing Non-Small Cell Lung Cancer Therapy Sequence Value

Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]

2021-03-23T18:59:56-04:00November 15th, 2018|News, Press, Publications|

IVI Releases Non-Small Cell Lung Cancer Patient Qualitative Research

IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression [...]

2020-03-19T15:44:59-04:00November 15th, 2018|News, Publications|
Go to Top